Great Basin Scientific initiates clinical trial

Great Basin Scientific Inc. (Nasdaq: GBSN) initiated a clinical trial for its Bordatella Direct Test to detect the Bordatella pertussis bacterium. The stock price leaped $1.00 to $2.73.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.